Pharmacophore Synergism in Diverse Scaffold Clinches in Aurora Kinase B

Aurora kinase B (AKB) is a crucial signaling kinase with an important role in cell division. Therefore, inhibition of AKB is an attractive approach to the treatment of cancer. In the present work, extensive quantitative structure–activity relationships (QSAR) analysis has been performed using a set of 561 structurally diverse aurora kinase B inhibitors. The Organization for Economic Cooperation and Development (OECD) guidelines were used to develop a QSAR model that has high statistical performance (R2tr = 0.815, Q2LMO = 0.808, R2ex = 0.814, CCCex = 0.899). The seven-variable-based newly developed QSAR model has an excellent balance of external predictive ability (Predictive QSAR) and mechanistic interpretation (Mechanistic QSAR). The QSAR analysis successfully identifies not only the visible pharmacophoric features but also the hidden features. The analysis indicates that the lipophilic and polar groups—especially the H-bond capable groups—must be present at a specific distance from each other. Moreover, the ring nitrogen and ring carbon atoms play important roles in determining the inhibitory activity for AKB. The analysis effectively captures reported as well as unreported pharmacophoric features. The results of the present analysis are also supported by the reported crystal structures of inhibitors bound to AKB.

[1]  S. N. Bukhari,et al.  Perceiving the Concealed and Unreported Pharmacophoric Features of the 5-Hydroxytryptamine Receptor Using Balanced QSAR Analysis , 2022, Pharmaceuticals.

[2]  M. Zaki,et al.  Mechanistic Analysis of Chemically Diverse Bromodomain-4 Inhibitors Using Balanced QSAR Analysis and Supported by X-ray Resolved Crystal Structures , 2022, Pharmaceuticals.

[3]  V. M. Patil,et al.  Exploring the Prominent and Concealed Inhibitory Features for Cytoplasmic Isoforms of Hsp90 Using QSAR Analysis , 2022, Pharmaceuticals.

[4]  Wei-Chang Fu,et al.  Discovery of a novel Aurora B inhibitor GSK650394 with potent anticancer and anti-aspergillus fumigatus dual efficacies in vitro , 2021, Journal of enzyme inhibition and medicinal chemistry.

[5]  Christopher J. Woods,et al.  Exploration of the structural requirements of Aurora Kinase B inhibitors by a combined QSAR, modelling and molecular simulation approach , 2021, Scientific Reports.

[6]  Shi-wu Chen,et al.  Aurora kinase inhibitors: a patent review (2014-2020) , 2021, Expert opinion on therapeutic patents.

[7]  Z. Dong,et al.  Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy , 2021, Molecular cancer.

[8]  Paola Gramatica,et al.  Principles of QSAR Modeling , 2020 .

[9]  Ana Sovic Krzic,et al.  Estimation of Random Accuracy and its Use in Validation of Predictive Quality of Classification Models within Predictive Challenges , 2019, Croatica Chemica Acta.

[10]  B. Rogister,et al.  The functional diversity of Aurora kinases: a comprehensive review , 2018, Cell Division.

[11]  Roberto Todeschini,et al.  On the Misleading Use of QF32 for QSAR Model Comparison , 2018, Molecular informatics.

[12]  Andreas Bender,et al.  Identification of Novel Aurora Kinase A (AURKA) Inhibitors via Hierarchical Ligand-Based Virtual Screening , 2017, J. Chem. Inf. Model..

[13]  H. Bhatt,et al.  A comprehensive review on Aurora kinase: Small molecule inhibitors and clinical trial studies. , 2017, European journal of medicinal chemistry.

[14]  Vesna Rastija,et al.  PyDescriptor : A new PyMOL plugin for calculating thousands of easily understandable molecular descriptors , 2017 .

[15]  Shufeng Zhou,et al.  An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitor , 2016, Clinical and experimental pharmacology & physiology.

[16]  Inho Choi,et al.  Computer Aided Drug Design: Success and Limitations. , 2016, Current pharmaceutical design.

[17]  David A. Winkler,et al.  Understanding the Roles of the "Two QSARs" , 2016, J. Chem. Inf. Model..

[18]  S. Linardopoulos,et al.  Aurora Kinase Inhibitors: Current Status and Outlook , 2015, Front. Oncol..

[19]  Stephani Joy Y Macalino,et al.  Role of computer-aided drug design in modern drug discovery , 2015, Archives of Pharmacal Research.

[20]  P. Gramatica,et al.  Tautomerism and multiple modelling enhance the efficacy of QSAR: antimalarial activity of phosphoramidate and phosphorothioamidate analogues of amiprophos methyl , 2014, Medicinal Chemistry Research.

[21]  Paola Gramatica,et al.  External Evaluation of QSAR Models, in Addition to Cross‐Validation: Verification of Predictive Capability on Totally New Chemicals , 2014, Molecular informatics.

[22]  F. Villa,et al.  Structure of Aurora B–INCENP in complex with barasertib reveals a potential transinhibitory mechanism , 2014, Acta crystallographica. Section F, Structural biology communications.

[23]  A. Tropsha,et al.  Data Set Modelability by QSAR , 2014, J. Chem. Inf. Model..

[24]  J. Dearden,et al.  QSAR modeling: where have you been? Where are you going to? , 2014, Journal of medicinal chemistry.

[25]  Paola Gramatica,et al.  QSARINS: A new software for the development, analysis, and validation of QSAR MLR models , 2013, J. Comput. Chem..

[26]  Paola Gramatica,et al.  QSAR Modeling is not “Push a Button and Find a Correlation”: A Case Study of Toxicity of (Benzo‐)triazoles on Algae , 2012, Molecular informatics.

[27]  A. Tropsha,et al.  Does Rational Selection of Training and Test Sets Improve the Outcome of QSAR Modeling? , 2012, J. Chem. Inf. Model..

[28]  S. Knapp,et al.  Crystal Structure of Human Aurora B in Complex with INCENP and VX-680 , 2012, Journal of medicinal chemistry.

[29]  Paola Gramatica,et al.  Real External Predictivity of QSAR Models. Part 2. New Intercomparable Thresholds for Different Validation Criteria and the Need for Scatter Plot Inspection , 2012, J. Chem. Inf. Model..

[30]  D. Zheleva,et al.  Aurora kinase inhibitors: Progress towards the clinic , 2012, Investigational New Drugs.

[31]  Chris Morley,et al.  Open Babel: An open chemical toolbox , 2011, J. Cheminformatics.

[32]  Paola Gramatica,et al.  Real External Predictivity of QSAR Models: How To Evaluate It? Comparison of Different Validation Criteria and Proposal of Using the Concordance Correlation Coefficient , 2011, J. Chem. Inf. Model..

[33]  Paola Gramatica,et al.  QSAR model reproducibility and applicability: A case study of rate constants of hydroxyl radical reaction models applied to polybrominated diphenyl ethers and (benzo‐)triazoles , 2011, J. Comput. Chem..

[34]  P. Lan,et al.  3D-QSAR and molecular docking studies of azaindole derivatives as Aurora B kinase inhibitors , 2011, Journal of molecular modeling.

[35]  CHUN WEI YAP,et al.  PaDEL‐descriptor: An open source software to calculate molecular descriptors and fingerprints , 2011, J. Comput. Chem..

[36]  Xiaohui Fan,et al.  Why QSAR fails: an empirical evaluation using conventional computational approach. , 2011, Molecular pharmaceutics.

[37]  Igor V. Tetko,et al.  Applicability Domains for Classification Problems: Benchmarking of Distance to Models for Ames Mutagenicity Set , 2010, J. Chem. Inf. Model..

[38]  Alexander Tropsha,et al.  Trust, But Verify: On the Importance of Chemical Structure Curation in Cheminformatics and QSAR Modeling Research , 2010, J. Chem. Inf. Model..

[39]  M. Saif,et al.  Aurora kinase inhibitors as anti-cancer therapy , 2010, Anti-cancer drugs.

[40]  S. Cho,et al.  Structural studies of B-type Aurora kinase inhibitors using computational methods , 2010, Acta Pharmacologica Sinica.

[41]  R. Todeschini,et al.  Molecular Descriptors for Chemoinformatics: Volume I: Alphabetical Listing / Volume II: Appendices, References , 2009 .

[42]  G. Bottegoni,et al.  Small molecule aurora kinases inhibitors. , 2009, Current medicinal chemistry.

[43]  J. Pollard,et al.  Discovery and development of aurora kinase inhibitors as anticancer agents. , 2009, Journal of medicinal chemistry.

[44]  Stephen S. Taylor,et al.  Mitotic drivers—inhibitors of the Aurora B Kinase , 2009, Cancer and Metastasis Reviews.

[45]  Edward H. Kerns,et al.  Drug-like Properties: Concepts, Structure Design and Methods: from ADME to Toxicity Optimization , 2008 .

[46]  Alexander Golbraikh,et al.  Predictive QSAR modeling workflow, model applicability domains, and virtual screening. , 2007, Current pharmaceutical design.

[47]  Paola Gramatica,et al.  Principles of QSAR models validation: internal and external , 2007 .

[48]  Paola Gramatica,et al.  The Importance of Being Earnest: Validation is the Absolute Essential for Successful Application and Interpretation of QSPR Models , 2003 .

[49]  Douglas M. Hawkins,et al.  Assessing Model Fit by Cross-Validation , 2003, J. Chem. Inf. Comput. Sci..

[50]  James J. P. Stewart,et al.  MOPAC: A semiempirical molecular orbital program , 1990, J. Comput. Aided Mol. Des..

[51]  Jerzy Leszczynski,et al.  Applicability Domain: A Step Toward Confident Predictions and Decidability for QSAR Modeling. , 2018, Methods in molecular biology.

[52]  S. S. Imam,et al.  Computer Aided Drug Design: A Novel Loom To Drug Discovery , 2017 .

[53]  V. Rastija,et al.  Effect of information leakage and method of splitting (rational and random) on external predictive ability and behavior of different statistical parameters of QSAR model , 2014, Medicinal Chemistry Research.

[54]  Paola Gramatica,et al.  On the development and validation of QSAR models. , 2013, Methods in molecular biology.

[55]  V. Rastija,et al.  Does tautomerism influence the outcome of QSAR modeling? , 2013, Medicinal Chemistry Research.

[56]  Glenn Fung,et al.  On the Dangers of Cross-Validation. An Experimental Evaluation , 2008, SDM.

[57]  Roberto Todeschini,et al.  Handbook of Molecular Descriptors , 2002 .